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Abstract
Background
Pre-eclampsia (PE) is a complex, multi-systemic condition of pregnancy which greatly
impacts maternal and perinatal morbidity and mortality. MicroRNAs (miRs) are differen-
tially expressed in PE and may be important in helping to understand the condition and its
pathogenesis.
Methods
Case-control studies investigating expression of miRs in PE were collected through a sys-
tematic literature search. Data was extracted and compared from 58 studies to identify the
most promising miRs associated with PE pathogenesis and identify areas of methodology
which could account for often conflicting results.
Results
Some of the most frequently differentially expressed miRs in PE include miR-210, miR-223
and miR-126/126* which associate strongly with the etiological domains of hypoxia, immu-
nology and angiogenesis. Members of the miR-515 family belonging to the imprinted chro-
mosome 19 miR cluster with putative roles in trophoblast invasion were also found to be
differentially expressed. Certain miRs appear to associate with more severe forms of PE
such as miR-210 and the immune-related miR-181a and miR-15 families. Patterns of miR
expression may help pinpoint key pathways (e.g. IL-6/miR-223/STAT3) and aid in untan-
gling the heterogeneous nature of PE. The detectable presence of many PE-associated
miRs in antenatal circulatory samples suggests their usefulness as predictive biomarkers.
Further progress in ascertaining the clinical value of miRs and in understanding how they
might contribute to pathogenesis is predicated upon resolving current methodological chal-
lenges in studies. These include differences in diagnostic criteria, cohort characteristics,
sampling technique, RNA isolation and platform-dependent variation in miR profiling.
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Conclusion
Reviewing studies of PE-associated miRs has revealed their potential as informants of
underlying target genes and pathways relating to PE pathogenesis. However, the incongru-
ity in results across current studies hampers their capacity to be useful biomarkers of the
condition.
Introduction
Few conditions which affect pregnancies are as prevalent, threatening and as steeped in theory
as pre-eclampsia (PE)—a multi-factorial, systemic and almost entirely human condition. PE
remains one of the primary drivers of maternal and perinatal morbidity and mortality through-
out the world, besetting up to 8% of all pregnancies, causing 10% of maternal deaths and
responsible for nearly 5% of stillbirths in the UK [1,2]. Typically occurring during the 3rd tri-
mester, this condition bears with it characteristic symptoms which include hypertension and
proteinuria [3]. Though primarily regarded as a hypertensive condition, the dangers of PE
extend beyond, into a multitude of systemic effects such as renal failure, pancreatitis and hae-
molytic anaemia [4]. Symptoms often surface in normotensive, non-proteinuric women and
emerge in grades of severity, which can progress towards the grand-mal seizures of eclampsia
and ultimately systemic maternal organ damage or death [5].
Proposed aetiological domains for PE span the fields of genetics, immunology and endocri-
nology. Implicated risk factors include maternal age, nulliparity and the presence of pre-exist-
ing conditions such as diabetes or hypertension [6]. Ethnicity, including mixed ethnicities, may
also be a contributing factor [7]. These risk factors are entwined with socioeconomic factors,
where individuals from lower socioeconomic backgrounds are at a heightened risk of PE [8].
The breadth of risk and adverse outcomes highlights the importance of early diagnosis—how-
ever, a consistently agreed-upon definition and classification of PE remains a contentious
issue. PE is generally classified into mild (mPE) and severe (sPE) using thresholds parameters
for systolic blood pressure, diastolic blood pressure and proteinuria; typically in accordance
with ISSHP criteria [9]. This is in contrast with temporal classification into early- (eoPE) and
late-onset PE (loPE), usually assigned in accordance with the presentation of PE features at ges-
tational age (GA) thresholds of either<34 weeks or>34 weeks respectively [10].
As PE pathology can be progressive, classification into mild and severe may not accurately
depict the risk associated with the opaque and transient nature of the condition. For example,
around 10% of women have no presence of hypertension or proteinuria within a week of their
initial eclamptic episode [11]. In lieu of this, the presence of severe features alongside baseline
PE symptoms has been suggested [12]. PE is also frequently co-morbid with other conditions
such as intra-uterine growth restriction (IUGR) or small-for-gestational age (SGA), and symp-
toms can often “mimic”, or overlap, with those of other syndromes such as HELPP syndrome
—making diagnosis a distinctly non-trivial matter [13]. Coupled with clinical pressures sur-
rounding the risk of under-diagnosis, this has resulted in a dilution of diagnostic specificity for
PE [14]. There is, therefore, a need to clarify the underlying pathogenic mechanisms of PE, in
order to unambiguously distinguish the condition and open the doors to early prognostic and
therapeutic measures.
The central hypothesis for understanding PE pathogenesis consists of two stages: starting
with abnormal placentation and uteroplacental ischemia early in pregnancy and progressing
towards a maternal inflammatory response [5]. In normal pregnancy, invasion of the decidual
Systematic Review of Micro-RNA Expression in Pre-Eclampsia
PLOS ONE | DOI:10.1371/journal.pone.0160808 August 16, 2016 2 / 36
Competing Interests: The authors have declared
that no competing interests exist.
Abbreviations: PE, Pre-eclampsia / Pre-eclamptic;
eoPE / loPE, Early-onset pre-eclampsia / Late-onset
pre-eclampsia; mPE / sPE, Mild pre-eclampsia /
Severe pre-eclampsia; miR, microRNA; FC, Fold-
change; GA, Gestational age; IUGR, Intra-uterine
growth restriction; SGA, Small-for-gestational age;
qRT-PCR, Quantitative reverse transcription PCR;
NGS, Next-generation sequencing; HIF-1α, Hypoxia-
inducible factor 1α; TLR, Toll-like receptor; STAT,
Signal transducer and activator of transcription; FOX,
Forkhead box protein; PIK3R2, Phosphoinositide-3-
kinase regulatory subunit 2; PI3K,
Phosphatidylinositide 3-kinase; C19MC,
Chromosome 19 microRNA cluster.
lining by fetally-derived extravillous trophoblasts surrounding the incipient blastocyst is a cru-
cial step in remodelling the maternal spiral arteries to adequately perfuse the developing pla-
centa and fetus [15]. Interstitial trophoblasts invade the myometrium layer of the uterine wall,
releasing vasodilatory factors such as nitric oxide, preparing the spiral arteries ahead of invasion,
attachment, destruction and replacement of the arterial lining by endovascular cytotrophoblasts
[14]. In PE, inadequate remodelling of the spiral arteries by these invasive trophoblasts is
thought to result in under-perfusion of the placenta.
A number of theories have been proposed to account for defective arterial remodelling at
this stage. Firstly, endovascular trophoblasts with particular haplotypes of the cell-surface
human leukocyte antigen may interact with natural killer cells and T-cells of the maternal
immune system in ways that could affect normal maternal-foetal immune adaptation [16,17].
Secondly, improper preconditioning of the uterus through menstruation has been proposed to
be a cause [18].
Thirdly, as invasion is predicated upon an increase in oxygen tension associated with a rise
in blood flow in early pregnancy; it is possible that impaired invasion is a consequence of dis-
turbed maternal blood flow prior to impaired spiral artery remodelling [19]. Lastly, dysregula-
tion of a number of key angiogenic factors, such as vascular endothelial growth factor (VEGF)
and its receptor, VEGF receptor-1 (Flt-1), have garnered attention as being important contrib-
utors of abnormal placental vasculature and the downstream effects [20]. It is for many of the
aforementioned reasons that Steegers et al. [3] described PE as a “disease of failed interaction
between two genetically different organisms”.
Following abnormal placentation, the combined ischemia-induced oxidative stress leads to
the release of inflammatory mediators into maternal circulation from the placental intervillous
space, including the anti-angiogenic factors endoglin and sFlt-1 [21]. Dysfunction of the all-
encompassing endothelium layer which lines the circulatory system is a consequence of the
inflammatory response induced by these mediators. For example, soluble Flt-1 (sFlt-1) can
absorb free VEGF and placental growth factor (PlGF), thereby effectively blocking downstream
vascular development [22]. This can lead to impaired sodium homeostasis of the renal system
and other systemic abnormalities [15]. Given the many pathways implicated in leading to PE, a
number of studies have been conducted to examine differences in gene expression in PE pla-
centas. These studies have largely been successful in finding significant differential expression
of genes in PE individuals within pathways relevant to proposed theories [23]. However, the
overarching regulatory mechanisms governing these expression changes remain unclear, and
represent a promising area of research towards finding a predictive model to connect the multi-
ple, intertwining routes towards PE.
MicroRNAs (miRs) are small, non-coding RNAs of around 22 nucleotides in length with
fundamental roles in regulating diverse biological processes including cell differentiation, apo-
ptosis and development. Their primary regulatory role derives from post-transcriptional gene
regulation, where partial or complete binding of miR “seed” regions to the 3’ untranslated
region of mRNAs promotes degradation of mRNA transcripts and translational inhibition
[24].
Biogenesis of miRs begins with processing pre-miR genes into primary transcripts known as
pri-miRs and concludes, after interaction with cytoplasmic components such as DICER, with
the mature miR as part of an RNA-induced silencing complex along with one of many catalytic
argonaute proteins in the cytoplasm [25]. The mature “guide” strand acts through anti-sense
complementarity to target mRNAs, with each miR having the potential to modulate expression
of multiple genes, often in a manner specific to tissue type and developmental stage [24].
The relevance of miRs to pregnancy has been explored in studies noting their abundance in
human placenta, where precise temporal regulation of gene expression plays an integral part in
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developmental mechanisms. Further evidence comes from studies revealing the presence of
miR biogenesis components, such as Drosha and Dicer, within trophoblast cells [26]. Biogene-
sis of miRs is essential, as mice models lacking Dicer have deformed vessel formation with
embryos dying shortly into gestation [27]. Recently, syncytiotrophoblasts were shown to be a
source of miR-containing microvesicles known as exosomes which are released into circulation
and protected from RNAse degradation [28]. These placenta-derived, exosomal miRs may be
involved in maternal-foetal cell communication, with functions in adapting maternal immune
tolerance to the foetus. Indeed, studies have shown exosomes to have roles in immune-related
mechanisms such as T-cell signalling [29]. Thus, it appears that miRs play a unique part in pla-
cental development and in the progression of pregnancy in general.
Consolidating miRs within proposed mechanisms and clinical phenotypes of PE has been
the focus of a cavalcade of studies for almost a decade, since the first major study conducted by
Pineles et al. [30]. These studies invariably involve use of microarrays, qRT-PCR and next gen-
eration sequencing (NGS) techniques to divulge the aberrant expression of miRs in case-con-
trol studies consisting of individuals with PE and normotensive individuals with normally
progressing pregnancies. While studies initially focused on placental samples from term deliv-
eries, pre-term circulatory samples from PE cases were soon revealed to also harbour detectable
quantities of differentially expressed miRs.
However, despite the wealth of studies which have suggested an association of certain miRs
with PE, no consensus yet exists on which appear to most significantly contribute towards
pathogenesis of the condition, and how they may function in doing so.
Our hypothesis was that miRs have differing expression profiles in PE individuals, and that
aberrant expression has a contribution towards pathogenesis of the condition. This study
aimed to carry out a systematic literature review detailing the current knowledge encompassing
the contributions of miRs to PE pathogenesis, by collecting and comparing results of putatively
associated miRs from case-control studies dating back to 2007. Through examining validated
targets and pathways of these miRs, a deeper understanding of their involvement within pro-
posed pathogenic domains of interest, and usefulness as prognostic and therapeutic markers
can be gained. Additionally, any areas of uncertainty which emerge from a review of current
studies will be discussed. In doing so, it is hoped that clarification can be brought to the ambig-
uous, often contradictory, landscape in this research area and highlight those miRs which show
the greatest potential for involvement in PE pathogenesis.
Methods
Database search
This systematic literature review queried both PubMed (MEDLINE) andWeb of Science data-
bases for studies from the period between March 2007 and December 2015 using the following
combinations of keywords: "pre-eclampsia", "preeclampsia", "microRNA" and "miR". The wild-
card operator () was assigned to each keyword to catch all related terms. Search queries dif-
fered according to the database. For Web of Science, only study titles were searched to narrow
the result set, which was otherwise too broad in scope. In testing this approach, results returned
by use of these single queries included all relevant studies obtained through use of several
multi-keyword searches (e.g. “differential”, “expression”) cross-referenced with the primary
term of “pre-eclampsia” or “preeclampsia” (Fig 1).
Study selection
The overall search strategy was predicated upon progressively filtering studies to resolve a set
of the most relevant results based upon a pre-defined criterion:
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1. The study involves a biochemical investigation of differentially expressed miRs in any sam-
ple type (tissue, circulatory fluid or otherwise) between individuals with diagnosed pre-
eclampsia and suitable unaffected, normotensive controls using any viable technique
(microarrays, qRT-PCR etc.).
2. The study contains details of the methodology used for conducting the investigation. The
study includes data on some, if not all, of the discovered differentially expressed miRs. The
study has provided this data either within the article itself, or separately in S1 File.
3. The study has been published in a scientific journal and is available in English.
Studies were initially filtered by screening titles for evidence of duplication. Following this,
abstracts were fully screened to ascertain proximity to the above criteria. If an abstract was
ambiguous with regards to matching the criteria, or overly vague in content, the full text of
the study was subsequently screened to preclude the possibility of removing any potentially
Fig 1. Flow chart denoting the search procedure for this systematic review. This process was repeated
multiple times between September 2015 and December 2015.
doi:10.1371/journal.pone.0160808.g001
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pertinent results. Included studies were categorized according to their investigative approach:
screening or candidate (Fig 2).
Screening studies involved an ostensibly non-biased approach to profiling miR expression
in cases and controls. Candidate studies, by contrast, involved a putative miR or set of miRs for
profiling. If a different cohort was used in a screening study for validating a subset of profiled
miRs, this validation set was considered to be a separate candidate study. In this way, the com-
bined total of screening and candidate studies surpassed the 58 studies included.
Data collection
For each study, data was independently extracted regarding miRs determined to be signifi-
cantly differentially expressed as defined by the study’s criteria for significance, with p-value
and fold change (FC) serving as the most commonly used parameters. Other comparative ele-
ments extracted from each study included cohort characteristics (e.g. sample size, ethnicity),
processing method (e.g. RNA extraction kit) and additional information for use in comparing
methodologies.
In studies which investigated cases of PE comorbid with other pregnancy-related condi-
tions, such as IUGR, only miRs reported to be significantly differentially expressed between PE
and control groups were included—subject to this information being available.
Data comparison
Using the information extracted from each study, an algorithm was written in the PHP script-
ing language to compare and count miRs from every included study (Fig 3).
While other comparative elements formed the core of discussing methodological differences
among studies, data from this algorithm was integral to informing the question of how miRs
might contribute to PE pathogenesis. Full data resulting from this algorithm is available sepa-
rately (S1 File).
For investigating miRs in mPE and sPE cases, the results included were those stated to be
significantly differentially expressed exclusively between mPE/sPE cases and normotensive
controls, and not between mPE and sPE in case-case comparisons. Furthermore, if the same
miR in a study was significantly differentially expressed in both mPE and sPE cases as com-
pared to controls, the miR was only included if its direction of change contrasted between
mPE and sPE. This was in order to facilitate the examination of miRs which may discriminate
between mild and severe forms of PE.
Studies which stratified PE cases by mild and severe used varying diagnostic criteria—such
as ISSHP, ACOG andWilliam’s Obstetrics 23rd edition [9,12,31]. While these overlapped with
respect to threshold clinical parameters for systolic and diastolic blood pressure, the require-
ment and quantity of proteinuria differed between criteria. For example, ACOG stipulates no
proteinuria requirement; instead sPE diagnosis is based on the additional presence of systemic
involvement [12].
Data investigation
Several bioinformatics tools were used to further investigate data. Both mirBASE and miRNA-
VISA were used to identify and explore miR families [32,33]. For investigating miR gene targets
and common pathways, DIANAmirPath v3.0 and Targetscan were utilized [34,35]. Ulti-
mately, reported biochemical verification of putative targets through the included and wider
literature served as the most reliable and concrete means of ascertaining any significance to PE
aetiology.
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Results
MicroRNAs of interest to PE
To address the question of how miRs may contribute to PE pathogenesis, this systematic review
first broadly determined those miRs most frequently detected with demonstrable patterns of
significant differential expression across all included screening studies (Fig 4 and Table 1).
While this data provides insight into miRs with suspected PE-related associations, it lends
no credence to any causal role in pathogenesis. To examine the potential contributions to PE
pathogenesis, two of the most frequently detected differentially expressed miRs,miR-210 and
Fig 2. Charts depicting the included screening and candidate studies split by sample type. Some individual studies examined miR
expression in multiple sample types.
doi:10.1371/journal.pone.0160808.g002
Fig 3. Flow chart depicting the systematic comparison of miRs across studies. Input data was collected from all studies included
within the systematic review.
doi:10.1371/journal.pone.0160808.g003
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Fig 4. Direction of expression of the most frequently discovered differentially expressed miRs. Border colour represents consensus
direction of change across all screening studies for the top 10 miRs.
doi:10.1371/journal.pone.0160808.g004
Table 1. List of the 20miRsmost frequently found to be differentially expressed across screening studies of PE.
miR Validated?a Cited Validated Targetsb References
223 Yes 9 GZMB, STAT3, E2F1, FOXO1 [36–44]
210 Yes 9 HSD17B1, ISCU, EFNA3, HOXA9 [30,41,44–50]
518b Yes 6 FOXN1, RAP1B [38–41,44,48]
181a Yes 6 (5p) BIRC6, (3p) CBX5 [41,44,47,50–52]
584 Yes 5 PURB, CUL2, (5p) KPNB1 [41,44,45,47,50]
517c Yes 5 Pyk2, (3p) NFIB [38,39,42,46,53]
16 Yes 5 BLC-2, CCNE1 [43,50–52,54]
18a Yes 5 TAOK2, (5p) INADL, (3p) SRF [39,41,44,46,53]
363 Yes 4 (3p) CDKN1A [36,41,44,50]
126* 4 MYC, (5p) SLC45A3 [38,44,46,53]
130a 4 - [38,39,52,53]
29a Yes 4 - [38,39,42,53]
29b Yes 4 - [39,43,51,54]
335 Yes 4 - [47,48,50,51]
126 Yes 4 - [47,48,51,53]
19a 4 - [39,41,44,46]
182 4 - [30,39,47,50]
144 Yes 4 - [39,44,48,52]
101 Yes 3 - [36,39,44]
26b Yes 3 - [37,39,51]
aValidation column states whether or not this miR has been validated by separate qRT-PCR investigation.
bValidated targets were collected from candidate studies and use of DIANA-TarBase v7.0 and TargetScan.
*Denotes the minor strand of this miR, as described by the study.
An extensive list of all differentially expressed miRs across studies can be found in S1 File.
doi:10.1371/journal.pone.0160808.t001
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miR-223, will be explored in greater detail through a review of the included candidate studies,
and wider literature. Combining -3p and -5p strand variants of all PE-associated miRs allows
for an observation of miR genes commonly associated with PE. Interestingly, bothmiR-126
andmiR-126 (miR-126-5p) are cited equally as frequently across screening studies and derive
from the same precursor gene. As miR-126 has been the subject of early therapeutic investiga-
tions, its potential involvement in PE will also be elucidated. Together, these miRs regulate
some of the main pathways proposed to account for PE aetiology: ischemia/hypoxia, immunity
and angiogenesis/vasculogenesis.
PE & Hypoxia—miR-210
A paucity of oxygen in the 1st trimester results in the creation of a hypoxic environment which
encourages trophoblast proliferation, and leads to increased expression of hypoxia-inducible
factor 1α (HIF-1α) in cytotrophoblasts [5]. While hypoxia cedes in normal pregnancy towards
the 2nd trimester, persistent ischemia in PE is met with continually high expression of HIF-1α
and other hypoxia-inducible elements, such as sFlt-1, in the placenta [55]. Prolonged hypoxia
in PE has been attributed to defects in maternal blood flow and/or trophoblast interactions,
key factors otherwise responsible for increased oxidative stress and trophoblast invasiveness
[3].
Of the 23 hypoxia-regulated miRs detected by Kulshreshtha et al. [56], around 18/23 are
present in PE across all screening studies included in this review, suggesting the integral nature
of hypoxia to pathogenesis (S1 File). Among these, miR-210 has emerged as one of the most
prevalent PE-associated miRs. It is increased as much as 13-fold in several hypoxia-induced
trophoblast cell lines, with levels maintainable for around 72 hours thereafter [57]. Significant
differential expression of miR-210 has been detected in both placenta and circulation in early
and late term PE individuals, through screening studies based on microarrays, NGS and
qRT-PCR. It is overwhelmingly found to be upregulated, and primarily in individuals with sPE
[30,44]. In a case-case analysis, Murphy et al. [58] discovered miR-210 levels in plasma to be
increased between mPE and sPE samples. Given that more severe forms of PE may be associ-
ated with increased hypoxia, and the hypoxic dose-dependent nature of miR-210 expression
observed by Fasanaro et al. [59], increased hypoxia-driven trophoblast cell debris likely results
in higher levels of miR-210 in circulation. Contrary to most studies, both Zhu et al. [44] and
Enquobahrie et al. [60] observed significant downregulation of miR-210 in mPE. This is per-
haps due to use of random placental samples and amnion samples in these studies respectively,
where different placental regions may differ in levels of hypoxia, made all the less consistent in
milder forms of PE.
Hypoxia may contribute to PE pathogenesis through the mediating effects induced by miR-
210. The hypoxia-sensitive HIF-1α and NF-κB have been found through ChIP and Luciferase
investigations to both bind to the miR-210 promoter and induce expression in a synergistic,
co-regulatory manner [57,61]. In trophoblast cells, ectopic expression of miR-210 greatly com-
promises invasiveness, with the phenotype partially rescuable using high-affinity, anti-miR-
210 oligonucleotides [57,62,63]. The mechanisms behind impaired invasiveness appear mani-
fold. It has been suggested that miR-210 inhibits trophoblast invasion via the MAPK and ERK
signalling pathways, in a manner inducible by both hypoxia and inflammation [62]. Luo et al.
[63] demonstrated that overexpression of KCMF1, a potassium channel modulator factor and
direct target of miR-210 found to be lower in PE individuals, rescued inhibition of trophoblast
invasion.
Though a particularly well-studied example, miR-210 represents just one of many PE-related
miRs demonstrated to hamper trophoblast invasiveness upon overexpression, including: miR-
Systematic Review of Micro-RNA Expression in Pre-Eclampsia
PLOS ONE | DOI:10.1371/journal.pone.0160808 August 16, 2016 9 / 36
376c, -155, -34a and -20a [63–66]. Thus, it appears trophoblast invasion is tightly regulated
through several, likely overlapping pathways. Whether aberrant expression of miR-210 is an ini-
tial cause of defective spiral artery remodelling, or a downstream consequence of the pathogenic
cascade, such as an abnormal immunological response, is unclear. Support for an immunological
link comes from Kopriva et al. [67], who described greatly increased levels of HIF-1α, NF- κB
and miR-210 after poly I:C stimulation of Toll-like receptor (TLR) 3 in pregnant mice which
developed PE-like symptoms, and in cultured human cytotrophoblasts. TLRs are prevalent in
utero-placental tissues where TLR3 recognizes double-stranded RNA viruses of the kind which
poly:IC simulates. While TLR3-activated pregnant mice developed hypertension, TLR3 knock-
out mice induced with poly:IC did not, nor did levels of miR-210, HIF-1α and NF- κB increase
significantly [67]. In combination with the suggested increased risk of PE in women with viral
infections, and the greatly increased miR-210 expression in activated T-cells, this lends credence
to a miR-210-mediated immunological pathway involved in PE pathogenesis [68,69].
Hundreds of gene targets have been predicted for miR-210 through in silico searches, but as
with miRs in general, the precise function is largely dependent on the cellular context.
Lee et al. [70] verified iron-sulfur scaffold homologue (ISCU) to be a target of miR-210,
finding decreased levels in both PE and SGA in line with increased miR-210 expression under
hypoxic conditions and consistent with studies of ISCU in relation to cancer and cardiovascu-
lar biology. ISCU is one of many proteins which make up the iron-sulfur clusters involved in
the electron transport chain and oxidation-reduction reactions within mitochondria. In this
way, miR-210 may be an important contributor towards the long-recognized increased oxida-
tive stress and mitochondrial abnormalities in PE, the latter of which has been shown to be
ameliorated by using miR-210 inhibitors [71,72].
Kopriva et al. [67] demonstrated signal transducer and activator of transcription 6 (STAT6)
to be a direct target of miR-210, observing decreased IL-4 expression coinciding with decreased
STAT6. Ishibashi et al. [46] found that miR-210 targeted the enzyme 17-beta-hydroxysteroid
dehydrogenase (HSD17B1) responsible for catalysing the production of estrone into 17β-estra-
diol. The level of 17β-estradiol is known to be lower in women with sPE, and is expressed
exclusively in the placenta [73]. This is one of many estrogen-catabolizing enzymes with noted
dysfunction in PE individuals, the prototypical example being catechol O-methyltransferase
[74]. Lastly, both Fasanaro et al. [59] and Zhang et al. [57] verified Ephrin-A3 (EFNA3) as a
target of miR-210. Among functions in embryonic development, Ephrins are important for
vascular development and cell migration, particularly in the cardiovascular system. Inhibition
of miR-210 and use of an EFNA3 allele lacking the miR-210 binding site both successfully abro-
gated the downregulation of Ephrin-A3 under hypoxic conditions. With these targets in mind,
and the elucidated feed-forward loop which is suggested to exist with HIF1α, miR-210 appears
to be an important player contributing to PE pathogenesis via hypoxia-induced factors [75].
PE & Immunology—miR-223
Given the connections between PE and immunological adaptation, it is interesting that one of
the most prevalent miRs across screening studies is often described in relation to immune tol-
erance and the inflammatory response, miR-223. In as much as miR-223 is studied in other
conditions, comparatively little is known about its contribution to PE. It is generally found to
be downregulated in sPE and eoPE, both in placental and circulatory samples (S1 File).
The highly-conserved gene encoding miR-223 is located on the X-chromosome, where the
promoter has demonstrated specificity for the haematopoietic system with roles which include
regulation of haematopoetic cell differentiation, quelling inflammatory response during infec-
tions and platelet adhesion [76,77]. While myeloid cells, particularly granulocytes, show high
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levels of miR-223, expression has also been noted in murine macrophages and resting natural
killer cells—where levels in both decrease upon cytokine activation [78–80]. Natural killer cells
are abundant in the placenta during early pregnancy and have suggested roles in establishing
tolerance to the newly implanted blastocyst [17]. Given this, decreased placental miR-223 in
early pregnancy may serve as an early predictive marker of aberrant natural killer cell-related
tolerance. In placenta, miR-223 was found to be expressed in both chorionic and basal plates,
in somewhat stark contrast to many other PE-associated miRs such as miR-210, which appear
to be preferentially expressed in either region [41]. The seemingly ubiquitous nature of miR-
223 may partially explain its prevalence in studies using random placental sampling.
Downregulation of miR-223 has been noted in obesity, inflammatory diseases, cancers and
autoimmune diseases such as type 2 diabetes [76]. In order to investigate possible pathways
and target genes for miR-223 of relevance to PE, the DIANA mirPath v3.0 tool was employed.
Validated targets were found in pathways predictably relating to cancer, but also FoxO signal-
ling—including STAT3 in both pathways and forkhead box protein (FOX) O1 in the latter.
FOXO1 localizes to the trophoblast layer of the choriodecidua and is a transcription factor
involved in regulating key cellular processes such as oxidative stress and apoptosis [81]. While
direct targeting of the 3’UTR of FOXO1mRNA by miR-223 has been demonstrated in cancer
cell lines, a significant decrease in FOXO1 expression has only been observed in mPE, and not
sPE [82,83]. STAT3 is a part of the STAT pathway which can be activated by both pro- and
anti-inflammatory cytokines, such as IL-6 which is itself increased after STAT3 phosphoryla-
tion [80]. Phosphorylated STAT3 under hypoxic conditions has been shown in multiple cancer
cell lines to stabilize and simultaneously bind with HIF-1α to separate sites on the VEGF pro-
moter, in order to maximally induce expression [84,85]. Interestingly, the PE-associated miR-
20b, part of the miR-106a/363 cluster, has also been shown to target STAT3 andHIF1A, and
no studies have found differential expression of both miR-20b and miR-223 together in PE
[86,87]. Similarly, miR-20a is upregulated in PE and directly targets FOXA1, perhaps suggest-
ing similar pathogenic pathways among these PE-associated miRs [65]. Chen et al. [80] found
that overexpressing miR-223 downregulated both IL-6 mRNA and protein production in poly
I:C-stimulated, TLR-activated macrophages by directly targeting murine STAT3 for transla-
tional inhibition.
Further exploration of the proposed IL-6/miR-223/STAT3 pathway using IL-6 specific anti-
bodies found the hugely reduced miR-223 levels after TLR-activation to be likely mediated by
IL-6, which in so doing, further increased IL-6 production in a positive regulatory manner.
Increased IL-6 has been shown to enhance vascular dysfunction and promote macrophage
infiltration, with downstream effects on cytotrophoblast invasiveness [88]. Additionally, treat-
ment of placental explants with IL-6 increased trophoblast shedding, with cells showing
reduced caspase activity [89]. Given immunohistochemical evidence of increased IL-6 levels in
PE individuals within decidual and cytotrophoblast cells, as well as in circulation, this may rep-
resent a novel pathway for miR-223 in PE pathogenesis [88,89].
A recent study by Schjenken et al. [90] suggested that expression of miR-223 may be
induced in tissues of the female reproductive tract after exposure to seminal fluid. Absence of
miR-223 then, could compromise immunological adaptation around conception. In the study,
miR-223 null mice had substantial changes in immune and inflammatory gene expression,
lower T-regulatory cell counts and as pregnancy progressed, a lower fetal:placental weight
ratio. Interestingly, this perhaps lends credence to a miR-223 role in prior observations of
maternal tolerance to paternal alloantigens being dependent on exposure to seminal fluid, as
well as the suggested increase in PE risk in nulliparous women below a certain age threshold
[91]. Lastly, there is compelling evidence that miR-223 may be involved in maintaining the qui-
escence of endothelial cells, where lower expression is met with the promotion of angiogenic
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status via increased β1-integrin expression [92]. Hypoxia has been shown to downregulate a
key upstream regulator of the miR-223 promoter, C/EBP-α, through HIF-1α [76,93]. Thus,
lower expression of miR-223 in PE could be a compensatory mechanism to reduce endothelial
quiescence and subsequently increase angiogenesis. With the wealth of potential connections
to PE pathogenesis in mind, further exploration of miR-223 in relation to PE is warranted.
PE & Angiogenesis—miR-126/126*
Impaired angiogenesis is a pillar of PE pathogenesis, and many PE-associated miRs are known
to have putative targets related to angiogenesis [51]. Of these, miR-126 represents one of the
most intimately connected, angiogenesis-related miRs. Encoded by the 7th intron of the EGFL7
gene in mammals, miR-126/126 is highly-conserved, being characterized in both mice and
zebrafish [94]. Endothelial cells, including those of the human umbilical vein, are highly
enriched for miR-126/126 and pivotal roles for this miR have been described in modulating
aspects of endothelial homeostasis—including enhancing the pro-angiogenic functions of
VEGF and fibroblast growth factors via the MAP kinase pathway [95]. That 40% ofmiR-126
knockout mice have an embryonic lethal phenotype while surviving mice show compromised
wound healing reflects the potent, albeit non-essential and context-dependent nature of miR-
126 expression in early development, and in maintaining angiogenic homeostasis thereafter
[95].
Significant differential expression of both miR-126 and miR-126 has been detected across
screening studies, but with no clear consensus on directions of change in PE (Table 2).
A general consensus towards increased miR-126 expression appears evident in placental
samples. For example, NGS studies by Guo et al. [38] and Yang et al. [53] both detected
increased miR-126 in mPE, while increased miR-126 in the study by Ishibashi et al. [46] was
detected in a cohort mainly consisting of individuals with the assumedly milder, loPE. Addi-
tionally, in determining expression from both mPE and sPE individuals, Zhu et al. [44]
detected decreased miR-126 in only the latter. Although functional differences between both
mature strands are not well understood, miR-126 may play a part in the arterial injury
response by targeting Dlk1, an inhibitor of Notch1 which negatives regulates endothelial cell
proliferation [98]. Mechanisms governing selection of the functionally active strand are
unclear, however. That expression of both strands in a non-mutually exclusive manner has
been observed in PE is intriguing, given the expected inhibitory outcome. An explanation for
Table 2. List of studies detecting differential expression of miR-126* or miR-126, with their respective directions of change.
Study type Study miR Sample type Direction of change (PE sub-type)
Screening [38] 126* Placenta Increase (higher in mPE)
Screening [51] 126 Placenta Increase (sPE)
Screening [46] 126* Placenta Increase (mostly loPE)
Screening [47] 126 Placenta Decrease (sPE)
Screening [48] 126 Serum Decrease (sPE)
Screening [53] 126,126* Placenta & Plasma Increasea
Screening [44] 126* Placenta Decrease (sPE)
Candidate [96] 126 Placenta Decrease
Candidate [97] 126 Placenta & EPCsb Decrease
aIn this study, miR-126 and -126* were upregulated in both placental and plasma samples with varying levels of expression between sample types and fold
change differences between mPE and sPE.
bEPC = Endothelial progenitor cell.
doi:10.1371/journal.pone.0160808.t002
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this may arise from evidence of different argonaute complexes integrating either miR strand,
allowing for coinciding functional roles [99]. Differential ratios of miR-126 strand expression
in PE classifications may reflect differences in pathogenetic mechanisms between mPE and
sPE, or in the adaptive response to varying degrees of angiogenic insult—perhaps through miR
arm switching [100].
Although unclear from screening studies alone, a consensus on decreased miR-126 expres-
sion appears evident from candidate studies of this miR (Table 2). As blood flow can activate a
pathway mediated by the zinc-finger transcription factor KLF2A towards inducing miR-126
expression in endothelial cells, the ischaemic consequences of PE could lead to an overall
decrease in miR-126 expression which correlates roughly with severity of the condition [101].
Evidence of the capacity for hypoxia to reduce miR-126 expression exists for RF/6A retinal
cells, and disturbed flow has been noted to also reduce levels of miR-126 [98,102]. An imbal-
ance of angiogenic factors in PE, including a reduction in pro-angiogenic VEGF-A, which has
roles in endothelial cell survival, may work in tandem with possible increased hypoxia in more
severe PE to reduce the density of endothelial cells and subsequently, miR-126 expression
[103]. Perhaps supporting this, Yan et al. [97] noted a decreased number of endothelial
progenitor cells (EPCs) in PE patients, which could be moderately correlated with miR-126
expression.
How miR-126 acts to influence the dynamics of angiogenesis has been reasonably well-stud-
ied outside of PE. For example, in chronic kidney disease, both miR-126 and miR-223 have
been noted to increase in the aortas of mouse models throughout disease progression [104]. In
the context of PE, a candidate study using qRT-PCR by Hong et al. [96] found significantly
lower miR-126 levels in placental samples from 115 PE cases, which positively correlated with
lower VEGFmRNA levels. Validated 3’UTR targets of miR-126 include phosphoinositide-
3-kinase regulatory subunit 2 (PIK3R2) and sprouty-related EVH1 domain—containing pro-
tein 1 (SPRED1), both integral components of the VEGF signalling pathway [105]. PIK3R2 is
known to be important in negatively regulating phosphatidylinositide 3-kinase (PI3K) and its
downstream target Akt, which it phosphorylates in a VEGF-induced manner with effects on
angiogenesis [105]. In a candidate study of miR-126 in EPCs, Yan et al. [97] found decreased
PIK3R2 expression after transfer of miR-126 mimics, with increased levels of mRNA and pro-
tein for both PI3K and Akt. The connection was reinforced by a PIK3R2 loss-of-function study
which revealed similar effects to the mimic.
Further inoculation of rat placentas with antagomir-126 revealed a reduction in the size and
weight of placentas, as well in microvessel density [97]. Rodents have hemochorial placentas,
much like humans, and share the placental processes of trophoblast invasion and artery remod-
elling. In a later animal model study, miR-126 was decreased by 57% in the placentas of rats
administered with the nitric oxide synthase inhibitor L-NAME, which effectively reproduces
the hypertensive and proteinuric effects of PE [106]. Interestingly, overexpressing agomir-126
alleviated many symptoms of placental dysfunction in PE rats, leading to better pregnancy out-
comes (e.g. higher microvessel density and pup/placenta weight) while having no significant
effect on PIK3R2 protein expression or on blood pressure. Regulation of blood pressure and
PIK3R2 expression by other factors likely accounts for some of these apparent discrepancies.
This may include additional targets of miR-126 in PE which are imperfectly emulated in the
L-NAME model, and which could result in compounded downstream effects on blood pressure
and PIK3R2 expression.
The authors suggested that variation in blood pressure within the small sample group and
lack of optimized treatment protocols may also be implicated. While hinting at the promise
and limitations of miR-126 for use in a therapeutic context, it is unknown how evaluations of
efficacy in rodent models would translate into the distinctly human manifestation of PE. Lastly,
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miR-126 has been shown to regulate Ephrin-B2 (EFNB2), an inhibitor of MAP kinase signal-
ling with roles further downstream of VEGF [105]. EFNB2 represents a common target of the
angiogenesis-related miR-20b, which shares a seed sequence with miR-17 and -20a and have
all similarly been found to be differentially expressed in individuals with sPE [87]. Given the
attention miR-126 has already received, subsequent elucidation of other downstream targets
and effects will allow for the already promising aspects of miR-126 in therapeutic intervention
to be thoroughly explored.
Familiar Territory—The C19MC Cluster
Organization of miRs into families based on common seed sequences with the assumption of
related targets has proven useful in cancers in informing patterns of interaction between related
miR entities [107]. To determine miR families with relevance to PE pathogenesis, the base miR
entities with markers of relatedness (e.g. miR-29a, -29b) and strands references (-3p, -5p) col-
lected together were split into groups across screening studies (Fig 5).
In so doing, 11 independent studies discovered members of the miR-515 family belonging
to the chromosome 19 miR cluster (C19MC) to be among the most represented across all
included screening studies (S1 File). The primate-specific C19MC is a paternally imprinted
cluster consisting of around 46 pre-miR genes spread across a 100kb region, with the miR-515
family comprising one of two large sub-groups within [108]. Members of the C19MC cluster
are highly enriched in placenta, particularly in term trophoblast cells where they comprise a
significant proportion of cellular miR content and demonstrate increased expression from 1st
to 3rd trimester [109,110]. Increased expression is paralleled in maternal circulation and
C19MC miRs compose the majority of exosomal miRs, where they could be important players
in cell-cell communication [109,111]. In regards to this, the extracellular-packaged C19MC
miRs in circulation have recently been shown to exhibit anti-viral activity in recipient cells,
somewhat reminiscent of prokaryotic RNAi immune mechanisms [112]. Given the prominent
expression of C19MC in normal placental physiology, it is expected that aberrant regulation
could have significant contributions towards PE pathogenesis.
This cluster has been the focus of several candidate studies, which generally conclude
C19MC members to be upregulated in cases of sPE and eoPE, in both plasma and placental
samples [113–116]. In normal pregnancy, miR-517b and miR-519a are suggested to be impor-
tant for regulating trophoblast proliferation in early gestation [117]. Anton et al. [114] found
that transfection of miR-517a/b, which have identical sequences, and miR-517c to first-trimes-
ter extravillous trophoblasts dramatically decreased invasiveness—also observing that these
miRs appeared to be increased under hypoxic conditions. While validated targets are conspicu-
ously lacking for miR-517a/b/c, increased expression was associated with increased sFlt-1 levels
along with the anti-angiogenic cytokine, TNFSF15. Little is known about the involvement of
miR-518b in PE, despite considerable evidence of its aberrant expression (Table 1). In embry-
onic carcinoma cells treated with BMP-2 to adopt an epithelial phenotype, miR-518b was
shown to directly target FOXN1—a transcription factor critical for thymus development and
epithelial differentiation [118]. Knockout mice for the Foxn1 gene are phenotypically hairless
("nude") and severely immunodeficient [119]. There is also indication from an oncological
study that upregulation of miR-518b is associated with inhibited cell migration in chondrosar-
coma cells [120].
Yang et al. [53] found miR-519d to be among the highest proportionally differentially
expressed miRs in PE cases, and corroborated the high expression of C19MC members in
plasma samples. Additional studies have reinforced upregulation of miR-519d in circulatory
samples from PE cases [39,42,116]. This miR has been associated with obesity, and a candidate
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study of miR-519d-3p in placenta by Ding et al. [115] suggested that by directly targeting the
3‘UTR of matrix metalloproteinase-2 (MMP-2), one of many extracellular matrix proteases,
miR-519d-3p was able to suppress trophoblast invasion and migration [121]. Further investi-
gation found MMP-2 to be reduced in the placentas of PE individuals and negatively correlated
with miR-519d-3p, though the effect of miR-519d-3p mimics onMMP-2 luciferase activity
after transfection appears modest. These results extend findings by Xie et al. [122] who
observed that miR-519d could reduce expression of Cxcl6, Foxl2 and NR4A2 transcripts, where
Cxcl6 and NR4A2 have previously described roles in cell migration in neutrophils and mesen-
chymal stromal cells respectively.
Lastly, after exposure of primary human trophoblasts to hypoxia, Donker et al. [109] found
miR-520c-3p to be selectively downregulated, with no significant effect on other C19MCmiRs.
This was reinforced in a screening study by Betoni et al. [36], perhaps suggesting a link between
hypoxia and downregulation of particular C19MCmembers. However, comparatively few
studies have since corroborated differential expression of miR-520c-3p in PE, with miR-517c
and miR-518b being the most widely detected PE-associated C19MCmembers across screen-
ing studies (S1 File).
As the C19MC cluster is expressed from the paternal chromosome and epigenetically-regu-
lated through an upstream CpG-rich site, increased C19MC expression throughout normal
pregnancy, and aberrant upregulation in PE, may be due to progressive loss of methylation
[123]. Indeed, significant hypomethylation at several gene loci has been associated with eoPE
and use of a demethylating agent in carcinoma cells restores C19MC expression [123,124].
Upregulation of C19MCmembers could then lead to a combinatorial effect on inhibition of
invasiveness. With this in mind, differential expression of the entire C19MC has been sug-
gested to account for differences between villous and extravillous trophoblasts, where the latter
Fig 5. Collection of basemiR groups containing putatively related, differentially expressedmembers across all
included screening studies.Group which consisted solely of the same repeated exact miR entity (e.g. miR-181a) were
removed. The miRs were grouped together into families using mirBASE and miRNAVISA. See S1 File for a full list of
specific miRs belonging to these groups and study references.
doi:10.1371/journal.pone.0160808.g005
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shows lower expression of the cluster and is responsible for invading the maternal decidua in
early gestation [122]. Overall, the C19MC cluster and families contained within represent an
incredibly promising and critically under-researched area, both for PE and understanding nor-
mal placental development. Additionally, from an evolutionary perspective, deeper study of
the C19MC could provide interesting clues towards advancing an understanding of how miR
clusters have contributed to the development of the primate lineage.
Discussion
Methodology comparison
This literature review accounted for 241 unique miRs across the included screening studies. Of
these, approximately 20% of the combined total were present in more than one study and veri-
fied by qRT-PCR either within the same screening study, or independently (Table 3).
The evident lack of congruity between results creates considerable doubt when assigning a
role for the huge variety of putative miRs in the pathogenesis of PE with any degree of certainty.
Differences in methodology likely play a significant part in creating variability between
results, particularly in areas such as the definition of PE, cohort characteristics, sampling tech-
nique, sample processing and data normalization. These suggested categories of methodologi-
cal incongruity will be explored.
Defining pre-eclampsia
Classification systems for PE employed by major organizations differ in ways that could mean-
ingfully impact studies. Areas of contention include: inclusion of non-proteinuric gestational
hypertension as PE, definition of severe hypertension, and relative consideration given to eoPE
[3]. In this review, it was noted that PE definitions were relatively consistent throughout, with
most studies opting to use ISSHP diagnostic criteria—even if not directly stated. Furthermore,
screening studies typically stratified PE cases by mild/severe and around half of all studies pro-
filed miR expression in only sPE cases, with average GAs at delivery ranging from 33–40
weeks. This highlights the variability in severity within sPE definitions alone. To determine
whether a selection of miRs could help delineate PE severity, all studies investigating differen-
tial expression in mPE and sPE cases were collected to examine miRs detected exclusively in
either so far. Some of the most frequently detected miRs in sPE cases whose aberrant expres-
sion had not been determined in mPE cases at the time of this review included: miR-181a,
-223, 195, -16, -18a and -363 [37,39,41,43,44,47,50–52,58,87,126,127].
It is worth noting that the absence of any putatively severe-associated miR from mPE does
not constitute its exclusive differential expression in sPE. However, it could indicate a correla-
tion between a detectably higher FC of the miR, and more severe forms of PE. For example,
miR-181a is one of the most independently validated miRs often associated with sPE, and has
been shown to modulate T-cell sensitivity/selectivity as well as enhance IL-6 expression in mes-
enchymal stem cells (Table 3)[126,128]. Most screening studies observing upregulation of
miR-181a, also noted upregulation of miR-210 [41,44,47,50,129]. These studies predominately
involved sPE cases, and a trend towards earlier delivery at around 34 weeks can be observed in
those reporting average GAs at delivery. Following this, the two studies finding miR-181a to be
upregulated without miR-210 involved late-onset sPE, with PE cohorts from both having later
average GAs at delivery of around 37 weeks [51,52]. This could indicate upregulation of miR-
181a coinciding with miR-210 to be a marker of more severe forms of sPE—perhaps implying
a particular pathogenetic route, e.g. immunological. That downregulation of miR-181a has also
been determined in placentas from pre-term deliveries at<35 weeks suggests that aberrant
expression of miR-181a is implicated in different pathogenic mechanisms relating to severe
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Table 3. List of PE-associated miRs from included screening studies which were found to be differen-
tially expressed in more than one independent study and validated by qRT-PCR.
miR References
223 [36–44]
210 [30,41,44–50]
518b [38–41,44,48]
181a [41,44,47,50–52]
584 [41,44,45,47,50]
517c [38,39,42,46,53]
16 [43,50–52,54]
18a [39,41,44,46,53]
363 [36,41,44,50]
29a [38,39,42,53]
29b [39,43,51,54]
335 [47,48,50,51]
126 [47,48,51,53]
144 [39,44,48,52]
101 [36,39,44]
26b [37,39,51]
25 [37,39,48]
1 [44,45,50]
195 [41,44,51]
214 [41,43,51]
519e* [41,44,46]
152 [44,47,48]
519d [39,42,53]
221 [39,43,52]
30a [39,43,54]
24 [39,40,52]
542-3p [41,42,44]
199b-5p [36,43]
140-5p [36,43]
342-3p [37,52]
296-5p [37,48]
26a [37,52]
141 [38,51]
149 [53,125]
20b [51,87]
193b [41,46]
526b [40,46]
20a [46,50]
377 [44,47]
519a [39,42]
520h [39,42]
100 [39,43]
19b [39,50]
495 [40,43]
30a-3p [41,44]
296 [41,44]
(Continued)
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pregnancy outcomes [40]. However, unlike miR-181a, differential expression of miR-210 has
also been observed in mPE—perhaps due to the sensitivity of its expression in a hypoxic envi-
ronment as previously discussed.
Members of the miR-15 precursor family, such as miR-16 and miR-195, are among the
most frequently associated with sPE and have been independently verified in multiple studies
(Table 3). Candidate studies revealed VEGFA to be a probable target of miR-16, which has pre-
viously been shown to regulate progression of the cell cycle and ameliorate decidual mesenchy-
mal stem cell proliferation in sPE, suggesting roles in impaired angiogenesis [43,54]. On the
other hand, miR-195 was found to modulate Activin/Nodal signalling through targeting
ActRIIA, and in so doing, promote invasiveness in a trophoblast cell line [127]. Given that the
effect on invasion is relatively minimal, other targets of this miR may also contribute towards
pathogenesis.
The inclusion of GA into PE classification is critical. A significant increase in maternal mor-
tality has been associated with eoPE, with the symptomatic chasm between eoPE and loPE
such that separate pathogenetic mechanisms with overlapping phenotypes have long been sus-
pected [130,131]. Although only 5–20% of cases are considered eoPE, in stark contrast to more
than 80% for loPE, these cases typically represent the most severe end of the symptomatic spec-
trum [132]. In assigning certain pathological features to eoPE, however, the co-existence of
IUGR in most eoPE cases muddies the water considerably, as many of the most severe symp-
toms in eoPE are also observed in isolated cases of IUGR [132]. Whether or not the included
cases of sPE in most studies also represent eoPE is uncertain, but the larger overall average
GAs at delivery may indicate severe loPE forms. A lack of consistency in eoPE and loPE defini-
tions was seen across all studies, with eoPE defined as either the onset of PE symptoms at<34
or<32 weeks, or by thresholds values for GA at delivery.
A screening study by Weedon-Fekjær et al. [49] detected a general over-representation of
aberrantly expressed miRs in eoPE (as defined by delivery at< 34 weeks), focusing upon
downregulation of miR-1301 which showed a correlation with foetal weight percentile in eoPE
cases (3 of which included IUGR). In a separate candidate study, expression of miR-517a/b/c,
members of the C19MC, were all significantly upregulated in eoPE in a manner that appeared
to correlate with severity [114]. Lastly, Gao et al. [133] found miR-675, encoded in the pater-
nally-imprinted and hypomethylatedH19 gene, to be downregulated significantly in eoPE.
This miR was demonstrated to inhibit trophoblast cell growth, possibly by targeting Nodal
Modulator 1 (NOMO1), an antagonist of the Nodal signalling pathway which is important for
regulating cell growth [133].
Where the contribution of a miR cannot be attributed to PE alone, as in studies involving
cases of PE co-morbid with conditions such as SGA, animal models can serve as a powerful
means to help resolve ambiguity. An example of this is in the screening study by Pineles et al.
[30], who detected differential expression of miR-155 in a cohort of PE individuals compli-
cated with SGA, but not in the group with PE alone. The PE+SGA group also had notably
Table 3. (Continued)
miR References
218 [41,44]
411 [41,44]
136 [42,43]
18b [44,53]
*Denotes the minor strand of this miR, as described by the study.
doi:10.1371/journal.pone.0160808.t003
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higher average values of systolic and diastolic blood pressure than the exclusively PE cohort.
The clarification of an association between miR-155 and PE arose from an animal study con-
ducted by Liu and Yang [134], who detected aberrant expression of miR-155 in L-NAME rat
models of PE.
Cohort characteristics
Among case and control groups from included studies, matching of characteristics generally
occurred for both GA at delivery and maternal age. Nulliparity was the most explicitly stated
characteristic to be additionally matched across screening studies. However, as with other char-
acteristics (e.g. ethnicity and BMI) matching infrequently reached significance after use of sta-
tistical testing, such as the Mann-Whitney rank-sum test. The most consistent differences in
PE cases as compared to controls, outside of diagnostic criteria, were increased nulliparity,
decreased GA at delivery and decreased foetal birth weight.
Ethnic composition was rarely indicated in studies. A study by Goodwin and Mercer [135]
found African-American women to be more likely to present with severe and persistent hyper-
tension. This may relate to findings of a pre-disposing polymorphism (G) of the human leuko-
cyte antigen occurring at higher frequencies within African-American populations [136]. In
the study by Pineles et al. [30], PE cases had among the lowest average GAs at delivery for the
sample size, and consisted of ethnically Black individuals. By contrast, a recent study found
ethnically Chinese individuals to have a lower prevalence of PE, as compared to Caucasians
[137]. Given this, and knowledge of population differences in allele frequencies of SNPs which
impact miR expression, the population included may influence variability in results [138]. In
combination with environmental and socioeconomic variations within populations, this could
meaningfully impact comparability between studies.
The vast majority of screening studies used PE cohort sizes of less than 10 individuals, par-
ticularly those involving microarrays (Fig 6).
In considering the apparent heterogeneous nature of PE pathogenesis, with multiple risk
factors and inherent genetic/environmental variability, these smaller cohort sizes may have a
reduced power to detect genuine differential expression of miRs.
Studies would therefore benefit from prior analysis to determine recommended sample
sizes for achieving the necessary statistical power. Lastly, few studies mentioned prior or on-
going treatment for PE in included cohorts, and it is unclear how treatment options, such as
use of anti-hypertensive medications, could impact expression patterns.
Sample, technique and timing
Technical and ethical reasons necessitate placental samples being taken after delivery, and it is
unknown how accurate miRs detected at this stage are in representing earlier pathological
mechanisms. Many studies have highlighted the tissue-specific, cell-specific and temporal
nature of miR expression during placental development [110,139]. This is particularly evident
between the 1st trimester and term periods, where changes in oxidative stress and trophoblast
proliferation are associated with a whirlwind of expressional changes [139,140]. For example,
levels of C19MC members significantly increase from 1st to 3rd trimester, while the opposite
rings true for the maternally-imprinted cluster on chromosome 14 [110]. Such changes may be
reflected in circulation, as reinforced by Pan et al. [141] who detected differential expression of
circulatory miRs before and after parturition. This highlights the importance of timing when
collecting samples, and the impact of circulatory miRs which can be detected practically at
timeframes prior to symptomatic onset and treatment.
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Across screening studies which profiled circulatory miRs, only Ura et al. [48] and Akehurst
et al. [142] included samples collected before the 3rd trimester, in plasma and serum samples
respectively, but with no overlap in results. While plasma and serum results are comparable,
serum samples have been noted to contain a higher level of miRs, suggested to be due to addi-
tional release of RNA from red blood cells during the coagulation process [143]. The placenta
is one of the most abundant sources of exosomal miRs, and many PE-associated miRs found
in placenta such as miR-210, -223, -181a, -126 and C19MCmembers, have also been observed
to be differentially expressed in circulation [28] (S1 File). This could indicate roles in cell-cell
(e.g. maternal-fetal) communication, or be merely a consequence of increased debris/apopto-
sis in cells in which they are highly expressed. In support of the former, there is evidence that
miR-223 can be transferred via high-density lipoproteins to endothelial cells where it is
thought not to be expressed, and from where it can target ICAM-1 [144]. Corroborating miRs
from results of antenatal circulatory profiling with those from tissue samples improves the
capacity to define miRs with a potential long-term involvement in PE pathogenesis. Interest-
ingly, some of the most frequently detected differentially expressed miRs across screening
studies have also only been described in placental samples thus far. Examples include miR-
584, and both miR-363 and -20 which are part of the miR-106a/363 cluster whose members
appear to associate with PE severity. Jiang et al. [47] found miR-584 to target endothelial nitric
oxide synthase (eNOS) and inhibit the migration of HTR8/SVneo trophoblast cells, although
Western blot and Transwell insert assays showed the effect to only be slight with use of miR-
584 mimics alone, in comparison to synergistic use with miR-355 which shares a target in
eNOS. Studies using samples from early in gestation have great potential in revealing miRs
which may only be transiently expressed, but with significance towards pathogenesis. This, in
turn, could prove important for the development of miR biomarkers to assist with the predic-
tion and diagnosis of PE.
Fig 6. Sample size groups used across all included screening studies.
doi:10.1371/journal.pone.0160808.g006
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The current predictive power of biomarkers for PE is limited. Viable biomarkers must be
sensitive and specific enough to distinguish PE from other hypertensive conditions of preg-
nancy, at a GA early enough to facilitate clinical intervention, while accounting for multiple
possible aetiological pathways. Given these requirements, a combination of biomarkers is likely
to be optimal [145]. Angiogenic and anti-angiogenic factors hold some promise in this regard,
with studies indicating their imbalance in maternal circulation to have predictive value for PE
and its severity [22,146–148]. Indeed, recently, a quantified ratio of two serum angiogenic fac-
tors, sFlt-1 and PlGF, was measured to have a positive and negative predictive value of 36.7%
and 99.3% respectively—an improvement upon traditional clinical parameters such as blood
pressure [149]. However, changes in the levels of circulatory sFlt-1 appear to be mainly signifi-
cant around 5 weeks prior to the onset of PE, and such changes may be more diagnostically
sensitive in women who later develop eoPE [148,150,151]. Moreover, impaired angiogenesis
alone is not pathognomonic of PE. Biomarkers are therefore unlikely to be prognostic in all
cases—although they may highlight some of the most severe [152]. It is among these reasons
that circulatory miRs may be of benefit. In the context of the suspected heterogeneity of PE,
miR biomarkers have the potential to reflect a wider range of indicted pathways, including
those involved in both eoPE and loPE, at more initial stages than is possible using angiogenic
markers. Evidence already exists that serum miR-210 expression can identify pregnant women
at risk for a hypertensive condition, including PE, at around 8–12 weeks prior to clinical onset
[62]. Use of such a marker would ideally need to be in conjunction with other potential PE-spe-
cific miR biomarkers within panels, before being tested for predictive capability in a large and
diverse prospective cohort. To that end, preliminary research using miR panels with samples
taken during the 1st trimester have suggested the viability of this method [153,154]. The future
feasibility of miRs in this clinically diagnostic context is contingent upon further study of their
altered expression at antenatal periods in PE individuals, as well as greater reproducibility in
results between such studies, taking into account the various factors discussed in this review.
In examining differences in sampling methodology which could account for variability in
results, crucial aspects include the timing and mode of delivery, as well as the sampling tech-
nique. Placental sample collection is a complex matter; collecting, processing and storage of
samples all require attention to maximize a sample’s representation of the in vivo state. The
timing of cord clamping can result in reduced placental weight, while labour-induced stress
(ischemia-reperfusion and compression) can result in increased activity of the free radical gen-
erating xanthine oxidase, in addition to gene expression changes [155]. Most studies opted to
match cases and controls for mode of delivery, while preferentially including individuals who
delivered by caesarean. This is a useful near-constant for comparing studies. In addition to
avoiding expression changes induced by labour and its associated stresses, matching cases with
elective caesareans in controls avoids over-representing non-PE induced caesarean deliveries
in control individuals.
One of the most significant sources of bias is in the sampling region. An oxygen gradient is
purported to exist from the central placental region to the periphery, where the periphery also
composes a larger portion of the total volume [155]. Therefore whole-tissue, or global sam-
pling, must take into account representative volume and oxygenation differences across the
placenta. Many studies omit details of sampled placental region, leaving the assumption of
global sampling. However, global sampling may neglect region-specific variation in miR
expression, masking differential expression in placental regions which may otherwise contrib-
ute towards pathogenesis. Wyatt et al. [156] found many hypoxia-related transcripts to have a
higher expression in the lateral-chorionic regions than in medial regions, including the hyp-
oxia-induced VEGF [157]. Differences in perfusability from medial to lateral regions across the
placenta are likely at least partially responsible for expression changes, as has been shown for
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certain anti-oxidant enzymes [158]. Importantly, regional variability has also been substanti-
ated for miRs in candidate studies which involved investigating expression specifically from
the chorionic and basal plates of the placenta (Table 4).
Spatial patterns of miR expression represent a key consideration when examining contribu-
tions to pathogenesis. Interestingly, there appears to be a clear dichotomy in direction of
change of differentially expressed miRs between chorionic and basal plates in PE, perhaps
reflecting changes in vasculature and oxygenation across placental regions. Localization of
miR-210 has previously been shown in the basal plate interstitial trophoblasts and in the syncy-
tiotrophoblasts of the chorionic villi, which sprout towards the basal plate—reinforcing studies
of its observed differential expression in basal plate samples [46,70]. Overall, regional expres-
sion differences highlighted here, including directions of change, correlate strongly with those
of hypoxia-regulated miRs from studies in cancer [160]. All included studies collected samples
from medial placental locations, near the umbilical insertion point. As is the case with hyp-
oxia-regulated transcripts such as connective tissue growth factor (CTGF) under normal physi-
ological conditions, it is expected that hypoxia-regulated miRs increase in expression from
medial to lateral regions—particularly in the chorionic plate. Given that CTFG has been shown
to increase VEGF-dependent angiogenesis via miR-210, it would be interesting to see if any
overlap in regional expression exists in PE [161].
The timing and storage of collected samples poses an addition layer of methodological chal-
lenge which could account for variability. Bravo et al. [162] emphasised the inherent instability
of miRs, demonstrating rapid degradation of samples stored at -80c for 3 days in a manner
which differed according to the specific miR and was seemingly unrelated to both isolation
method and relative abundance of the miR. Similarly, an investigation into plasma storage of
extracellular miRs found significant reductions in levels of particular miRs (including C19MC
members) after long-term storage of just over a year, with samples stored for< 2 months hav-
ing the least effect on degradation [163]. Differences in storage duration of used plasma sam-
ples could therefore have introduced bias into results from circulatory profiling studies. In the
included studies, the majority of placental samples were collected immediately after deliver and
either processed soon after, or snap-frozen at -80c for later processing. Two studies however,
by Choi et al. [37] and Noack et al. [129], profiled expression in formalin-fixed, paraffin-
embedded (FFPE) tissues. Both FFPE and frozen tissue samples are well-matched for making
comparisons, but FFPE tissue samples, as compared to cells, may harbour differences in miR
expression levels related to sample preparation [164,165]. It is thought that this may be due to
latent RNAse cleaving of precursor miRs in FFPE samples kept at room temperature.
Isolation and profiling
Prior to profiling, RNA extraction and isolation methods can significantly influence determi-
nations by defining the set of miRs available for discrete hybridization, amplification or
sequencing [166,167]. The majority of screening studies included in this review used isolation
methods based on either Guanidinium thiocyanate-phenol-chloroform (GTPC—e.g. TRIzol)
only, which isolates total RNA, or column-enrichment kits, which can enrich small RNAs
(Fig 7).
Podolska et al. [168] demonstrated that different RNA isolation techniques (GTPC or col-
umn-based) can result in distinctive microarray expression clusters, with some miRs appearing
particularly sensitive to bias in isolation procedure—including small nuclear RNAs typically
used as controls. RNA isolation kits have also been shown to differ in yield, purity and consis-
tency of captured RNAs [169]. While isolation methods were not all consistent across studies,
it can be considered a strength that most studies opted to use either TRIzol or mirVana. Of
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these, the latter may be more useful for NGS profiling with respect to the identification of miRs
and reproducibility [170].
The most utilised approaches for miR profiling are microarrays, qRT-PCR and NGS—each
bearing advantages and caveats which can have profound effects on results. Microarrays are
the most frequently employed across screening studies. Probe design for microarrays is a deli-
cate matter; probes must differentiate between precursor and mature miRs, highly-related
miRs (potentially differing by a single nucleotide) and account for differences in thermo-stabil-
ity between miRs. Considerable inter-platform differences between microarrays have been
noted, and the lack of consensus in microarray platform across screening studies may account
for observed variability [171,172]. Kuo et al. [173], in a comparison of all commercial and cus-
tom platforms, found less concordant results between different platforms, than between differ-
ent labs using the same platform. Differences in specificity and sensitivity of platforms (e.g.
probe design), platform-specific stringency criteria for detecting calls and downstream data
analysis are all likely to introduce bias [174]. The lack of sensitivity in microarrays may over-
look miRs which display inconsistent hybridization or amplification [175]. These factors
highlight the importance of rigorous and standardized approaches to microarray profiling,
appropriate normalization procedures and independent validation by NGS or qRT-PCR.
Table 4. List of differentially expressedmiRs found in chorionic and/or basal plate regions of PE placentas.
Chorionic Plate (Fetal) Both Plates Basal Plate (Maternal) Reference
No significant change N/A 125b-1-3p [159]
No significant change N/A 210 [63]
195, 18a, 379, 519e-5p, 17, 19b, 92a 223, 218, 411 210, 30a-3p, 518b, 524, 17-3p, 151, 193b, 214 [41]
18b, 19b 20b, 92a, 363 106a [50]
All studies included used qRT-PCR for determining expression levels. Samples were collected from a central placental location. Upregulated miRs are given
in italics. Downregulated miRs are not italicized.
doi:10.1371/journal.pone.0160808.t004
Fig 7. RNA extraction and isolationmethods used across all included screening studies.
doi:10.1371/journal.pone.0160808.g007
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The second most prolific profiling method is NGS, considered the new “gold standard”
technique in large-scale studies. The advantages of NGS compared to array-based platforms
include a determination of absolute miR quantity, uncovering novel miRs without a reliance
on pre-defined capture probes and detection of miR isoforms, or isomiRs [176]. For example,
Guo et al. [38] was able to conduct a study on isomiR expression between PE and control indi-
viduals, noting a greater representation of isomiRs with 3’additions in control samples as com-
pared to PE cases, where such additions could alter the stability and binding strength of miRs.
Most screening studies utilising NGS opted for SOLiD sequencing. In an investigation of these,
overlap existed in all SOLID-based studies profiling both placental and circulatory samples for
miR-29a and -517c (Fig 8c).
Interestingly, many of the overlapping miRs from SOLiD-based studies appear to be almost
exclusively from NGS-based studies. This perhaps reflects the sensitivity of this technology in
the detection of particular miRs, and is indicative of the comparability in results between
SOLiD-based studies. An additional candidate study utilising SOLiD sequencing by Pan et al.
[141] also detected differential expression of miR-29a and showed this to be significantly
downregulated after parturition in control cases. When Illumina-based studies were included
in the overlap investigation, miR-223 was among the most prevalent miRs detected in NGS
studies (4/6) and consistent representation of C19MC members in PE cases occurred in 5/6
NGS-based studies. A high correlation between SOLiD and Illumina sequencing technologies
has been demonstrated, as well as good comparability between SOLiD and qRT-PCR results—
further illustrating the benefits of NGS-based profiling methods [177].
Lastly, qRT-PCR has been considered the “gold standard” of small-scale miR measurement
due to its accuracy, sensitivity and specificity. Hence, qRT-PCR is typically used to validate
microarray or NGS results. Good intra-platform comparability reportedly exists between
Fig 8. Overlapping results from SOLiD-based NGS screening studies. a) Profiling in placental samples with similar methodologies b)
Profiling in circulatory (plasma/serum) samples c) Profiling across all sample types.
doi:10.1371/journal.pone.0160808.g008
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microarray and qRT-PCR results, with variability in FC values attributed to differences in
cDNA preparation or data normalization [171,175]. By contrast, array-based qRT-PCR results
have been noted to have a low correlation with microarrays, with the effect more prominent in
miRs with lower expression [178]. The sensitivity and low sample requirement of qRT-PCR is
particularly advantageous for evaluating circulating miR profiles, where levels of miRs may be
exceedingly low [179]. A subset of screening studies used qRT-PCR for profiling, often with
arrays (e.g. OpenArray) which have been demonstrated to be superior to traditional microar-
ray-based profiling [178]. However, interplatform differences have been shown to exist
between different qRT-PCR platforms when addressing the differential expression of miRs,
which could account for variability across qRT-PCR-based studies [180].
Data normalization
Normalization is an imperative step to eradicating technical bias not attributable to genuine
biological difference—for example, with RNA sampling and input. Lack of normalization with
microarrays has been shown to result in low conformity with qRT-PCR results [181]. For
microarray-based studies, no assumption can be made of uniformity in total miR content per
cell, nor of the quantity of miRs relative to total RNA, creating a challenge for standard normal-
ization methods. Of the few microarray studies which included details of normalization, aside
from typical methods of calculating mean spot intensities with or without subtracting the
median background, other methods involved relative adjustment to average intensity of a con-
trol miR (either added or endogenous), global median centring and locally weighted scatterplot
smoothing (LOESS). In a comparison of miR microarray normalization methods, Hua et al.
[181] noted that results normalized using LOESS had the highest correlation with qRT-PCR
results, though it is unlikely that this method will be suitable for all purposes—thus, the method
must fit the purpose.
Most qRT-PCR-based studies used small RNAs as internal controls for normalization: either
spiked-in cel-miR-39 (for circulatory determination) or the small nuclear RNA, U6 (Fig 9).
Fig 9. Internal controls used for qRT-PCR (both array-based and stem-loop) across screening and candidate studiesmainly
consisted of the small nuclear RNA, U6.
doi:10.1371/journal.pone.0160808.g009
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Conformity of internal controls can be considered a positive when collating results. How-
ever, most studies did not state prior validation of internal controls to ensure constant expres-
sion and suitability before use. The most frequently used endogenous control, U6, is processed
differently to miRs, meaning that expression could be altered under different experimental
conditions [176]. Presumptions of constant expression of well-used controls in all samples
under different experimental conditions can therefore lead to invalidating results. Alternative
normalization methods include global mean normalization, a method based on the mean
expression level of all detected miRs, which may be more suitable than use of endogenous con-
trols for profiling a large set of unbiased miRs in a genome-wide manner [182].
Where normalization of NGS data is concerned, both LOESS and quantile-based normaliza-
tion have been indicated to correlate well with qRT-PCR results [183]. A more recently pro-
posed, and perhaps simpler approach termed RUV (removed unwanted variation) was also
able to provide robust estimates in RNA-seq differential expression analyses, in some cases out-
performing cyclic LOESS and upper-quartile strategies, particularly when spiked-in RNA con-
trols were used [184]. However, as with normalization in general, any assumptions made by
the chosen method must be appropriate for the data under scrutiny.
Lastly, although FC is frequently used to quantify the differential expression of miRs, values
constituting meaningful change in vivo are unclear. Threshold values for FC significance varied
between studies; significant upregulation was generally considered to be a FC>2 or>1.5, with
few differentially expressed miRs showing a FC>3. However, even a large FC value for a miR
expressed at low levels does not confer any meaning for functional significance. This represents
an area of considerable uncertainty when comparing results and a weakness of this review is in
the inclusion of results proposed significant by each study, as determining an arbitrary global
significance threshold for FC would require access to raw data.
Conclusions
PE appears to be a heterogeneous condition within which many pathogenetic routes converg-
ing on similar phenotypes have been implicated—permitting it well deserving of its often-
claimed title as the “disease of theories”. Since the initial study delving into miR expression in
PE by Pineles et al. [30], a wave of studies examining miR expression in PE have steadily
emerged and the tide of data risen ever higher with no clear consensus on which, and how,
miRs may associate with pathogenesis.
In spite of this, and methodological variation among studies, certain miRs have emerged
repeatedly and appear to associate strongly with PE. Many elucidated in this review, such as
miR-210, miR-223 and miR-126/126, impinge on a spectrum of diseases. Through candidate
studies each can be intertwined with some proposed aspect of PE pathogenesis—as with hyp-
oxia and the HIF-1α/miR-210/ISCU pathway towards mitochondrial abnormalities. Other PE-
associated miRs segregate into distinct families with predominately placental expression pat-
terns, such as the prolific miR-515 family clustered within the expansive, primate-specific
C19MC. Epigenetic alterations may hold the key to aberrant expression of this cluster. This
paternally-imprinted cluster, whose members appear prevalent in secreted exosomes, could be
a means by which the fetus modulates adverse maternal immune responses. However, many
C19MC miRs, such as miR-518b, still lack verified target genes outside of cancer-based studies,
despite frequent association with PE. Further investigation is therefore essential in order to
understand their precise contributions. By expanding the question of contribution towards PE
classification, certain miRs appear to correlate with PE severity—as with miR-210, -223 and
-181a. Some miR families and clusters may also be closely tied to more severe forms of PE,
such as the miR-106a/363 cluster and miR-15 precursor family from which the prevalent miR-
Systematic Review of Micro-RNA Expression in Pre-Eclampsia
PLOS ONE | DOI:10.1371/journal.pone.0160808 August 16, 2016 26 / 36
195 and -16 emerge. Patterns of miR expression could help link similar pathological processes
to particular classifications of PE, resolving ambiguity, for example, between eoPE and sPE
cases. Exploring these questions further may therefore prove useful in disentangling the web of
PE definitions through strongly associating miRs linked to pathogenic pathways (e.g. IL-6/
miR-223/STAT3) and beyond this, for ascertaining the clinical value of miRs.
PE-associated miRs have the potential to serve as viable biomarkers of the condition. This
could be through the creation of miR-based panels with the capacity to aid in diagnosis, herald-
ing the onset and/or severity of PE. In a therapeutic context, transiently modulating the expres-
sion of genes implicated in pathways relating to pathogenesis using miR mimics and inhibitors
may also have clinical value, as with miR-126 mimics and the angiogenesis-related PIK3R2/
PI3K/Akt pathway. However, a current lack of consensus across studies with regards to PE-
associated miRs limits their capacity to be of wider, practical clinical value. Ultimately, any
clinical value is predicated upon resolving current methodological challenges which may
account for variability in results, allowing for a greater degree of standardization among stud-
ies. Challenges include the definition and classification of PE used, sampling technique, RNA
extraction method and crucially, the chosen platform for miR profiling. Furthermore, accurate
PE animal models will continue to prove important for allowing more rigorous determinations
of miR functionality in the context of entire biological systems.
Overall, this systematic review touches upon a promising and expanding area of research,
propelled by new technologies, such as NGS, which are better able to clarify the pictures
formed by prior studies, and driven by the ever-present threat of the condition. It is hoped that
further exploration of miR expression in PE, including a systems-level approach to unearthing
target genes and pathways, will continue to inform domains which may be of relevance to path-
ogenesis and advance our present understanding of PE.
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